Promoting Recovery in Schizophrenia: A Focus on Positive and Negative Symptoms

Psychiatry
Curriculum:
Promoting Recovery in Schizophrenia: A Focus on Positive and Negative Symptoms
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
November 12, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Psychiatrists, Psychiatry Nurse Practioners

Relevant Terms:

Schizophrenia

Christoph U. Correll, MD

Christoph U. Correll, MD
Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital
Investigator, Feinstein Institute for Medical Research
Associate Professor of Psychiatry
Hofstra North Shore LIJ School of Medicine
Adjunct Associate Professor of Psychiatry
Albert Einstein College of Medicine
Glen Oaks, NY

Christoph U. Correll, MD, is professor of psychiatry and molecular medicine at Hofstra North Shore-LIJ School of Medicine and medical director of the Recognition and Prevention (RAP) Program at the Zucker Hillside Hospital, both in New York. He is also the director of the Adverse Events Unit and the Core Laboratory Unit at the Zucker Hillside Hospital Advanced Center for Intervention and Services Research. 
 
Professor Correll completed his medical studies at the Free University of Berlin and Dundee University Medical School in Scotland. He is a board-certified general psychiatrist and child and adolescent psychiatrist, having trained at The Zucker Hillside Hospital in Queens, New York.
 
Professor Correll's research and clinical work focus on the identification, characterization, and treatment of adults and youth with severe psychiatric disorders. His areas of expertise include severe psychotic and mood disorders, including schizophrenia, bipolar disorder, and major depression, as well as aggressive spectrum disorders, including the prodrome, first episode, multi-episode and refractory illness phase. He further focuses on the risk-benefit evaluation of psychotropic medications, including the extent and mechanisms of cardiometabolic and neuromotor adverse effects.
 
Professor Correll has authored or co-authored over 200 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals, and is an editorial board member of nine scientific journals. He is the principal investigator or Steering Committee member of several large, federally funded grants and has received over two dozen national and international research awards and fellowships for his work.

Robert W. Buchanan, MD

Robert W. Buchanan, MD
Professor, Department of Psychiatry
University of Maryland School of Medicine
Maryland Psychiatric Research Center
Baltimore, MD

Robert W. Buchanan, MD, is currently Professor of Psychiatry in the Department of Psychiatry, University of Maryland School of Medicine; Interim Director, Maryland Psychiatric Research Center; Chief of the Maryland Psychiatric Research Center (MPRC) Outpatient Research Program; and Director of the Maryland Early Intervention Program. His major research interests include the neurobehavioral and neuroanatomical investigation of the pathophysiology of schizophrenia and the investigation of novel pharmacological approaches for negative symptoms, cognitive impairments, metabolic disturbances, and other side effects associated with antipsychotic treatment, and people with treatment-resistant schizophrenia. Dr. Buchanan has conducted a series of proof-of-concept and clinical trials examining antipsychotic-reduction strategies in the acute and maintenance treatment of schizophrenia; the use of adjunctive pharmacological agents for the treatment of negative symptoms and cognitive impairments; and the comparative efficacy of clozapine and olanzapine for positive and negative symptoms and cognitive impairment in partially responsive outpatients with schizophrenia. Currently, Dr. Buchanan is examining the use of combined anti-inflammatory agents for the treatment of persistent positive symptoms; the efficacy of oxytocin and galantamine for persistent negative symptoms and cognitive impairments; and the efficacy of an intervention, which combines oxytocin and a psychosocial intervention, for improving social function in people with schizophrenia. Dr. Buchanan has been involved in multiple aspects of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) project, including the identification of potential pharmacological targets for the treatment of cognitive impairments and the organization of the FDA/NIMH workshop to develop guidelines for the conduct of clinical trials of cognitive-enhancing drugs. He has served as Co-Principal Investigator on the Treatment Units for Research on Neurocognition and Schizophrenia (TURNS), was the Maryland Psychiatric Research Center site Principal Investigator, and was responsible for the design and conduct of TURNS clinical studies. Dr. Buchanan has had an ongoing role in the development and update of the Schizophrenia Patient Outcomes Research Team (PORT) psychopharmacological treatment recommendations. These are a set of evidence-based recommendations that have influenced the development of various sets of treatment algorithms and guidelines for schizophrenia.

Stephen R. Marder, MD

Stephen R. Marder, MD
Director, Section on Psychosis
Professor, Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
Professor in Residence, Semel Institute
University of California, Los Angeles
Los Angeles, CA

Stephen R. Marder, MD, received his undergraduate degree from the University of Pennsylvania and his medical degree from the State University of New York at Buffalo.  After an internship at Denver General Hospital he completed a residency at the University of Southern California.  From 1975 to 1977 he was a Clinical Associate in the Biological Psychiatry Branch at the National Institute of Mental Health.  In 1977 he joined the staff at the Brentwood VA Medical Center and the faculty at UCLA.
 
Dr. Marder's research has focused on the treatment of schizophrenia and the pharmacology of antipsychotic drugs.  He has authored or co-authored more than 200 journal articles and chapters based on research.  He is currently the Director of the VISN 22 Mental Illness Research, Education Clinical Center (MIRECC) for the Department of Veterans Affairs and the Director of the Section on Psychosis at the UCLA Semel Institute for Neuroscience and Human Behavior.  He was the leader of the NIMH MATRICS program for facilitating the development of drugs for improving neurocognition in schizophrenia and was the Principal Investigator of the NIMH Treatment Units for Research on Neurocognition in Schizophrenia (TURNS) and the Treatment and Evaluation Network for Experimental Targets in Schizophrenia (TENETS).  Dr. Marder is a member of the National VA Committee on the Seriously Mentally Ill.
 
Dr. Marder has received the Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill, the Stanley Dean Research Award of the American College of Psychiatry, the Alexander Gralnick Award from the American Psychiatric Association, the Outstanding Achievement Award of the Southern California Psychiatric Society,  the Kempf Award from the American Psychiatric Association,  the Wayne Fenton Award for Outstanding Clinical Care from the Schizophrenia Bulletin, and the American Psychiatric Association Award for Research in Psychiatry.  He is listed in The Best Doctors in America and America's Top Doctors.
1. Describe, evaluate, and diagnose positive and negative symptoms of schizophrenia
2. Recognize long-term consequences and functional implications of positive and negative symptoms
3. Describe the efficacy and safety of existing and emerging agents in the treatment of schizophrenia, with regard to treating both positive and negative symptoms
4. Implement psychosocial interventions and mechanisms for educating patients and caregivers regarding both positive and negative symptoms of schizophrenia and their functional impact

DISCLOSURE POLICY STATEMENT
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 

Faculty Disclosures
  • Christoph U. Correll, MD, has affiliations with Actelion, Alexza; Bristol-Myers Squibb, Cephalon, Eli Lilly, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Merck, Otsuka, Pfizer, ProPhase, Roche, Sunovion, Takeda, Teva, and Vanda (Consultant); Merck (non-promotional lecture only) (Speaker's Bureau); BMS, Janssen/J&J, and Otsuka (Research).
  • Robert W. Buchanan, MD, has affiliations with Abbott, Amgen, Bristol-Meyers-Squibb; En Vivo; Omeros; Roche (Consultant); Pfizer (Other: Data Safety Monitoring Board).
  • Stephen R. Marder, MD, has affiliations with Pfizer, Genentech, Abbott, Boeringer-Ingelheim, Lundbeck, BMS, Otsuka, Shire, Roche, Targacept (Consultant); Amgen, Sunovion (Research); MedAvante (Stockholder).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

RMEI, LLC
  • Jacqui Brooks, MBBCh, MRCPsych has no affiliations with commercial interests to disclose.
  • Cindy Kunzer has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated time to complete: 1 hour
Medium: Internet

FEE INFORMATION
There is no fee for this educational activity.

COMMERCIAL SUPPORT
This activity is jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine. RMEI gratefully acknowledges an educational grant from Genentech in support of this CME activity.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA Category 1 Credits™. A statement of credit will be available to print from your user history page.
  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 65% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8    
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above